11 January 2013 - 11 January 2013 - Phase III clinical trials for metastatic breast cancer have showed that a combination therapy significantly delays the progress of the disease, according to an interim analysis of the Turandot study by the Central European Cooperative Oncology Group (CECOG).

According to researchers of Vienna-based CECOG, the combination of Bevacizumab and Paclitaxel or Capecitabine considerably extends the time until disease progression versus chemotherapy alone, while increasing the response rate.

Products of targeted cancer therapy are almost always used in combination with traditional Zytostatika treatment, which improves the effect and inhibits the selection of resistant tumour cells.

The study involved 564 patients between September 2008 and August 2010 who were treated with Bevacizumab and Paclitaxel or Capecitabine until it came to disease progression. The study will be running at least until the end of 2014.